| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
β adrenergic receptor
Metoprolol-d7 hydrochloride targets the same molecular target as its non-deuterated form, the β₁-adrenoceptor. Metoprolol is a cardioselective β₁-adrenergic receptor antagonist that blocks the effects of catecholamines on the heart. By blocking β₁-receptors, metoprolol reduces heart rate, contractility, and cardiac output. It has minimal activity at β₂-receptors, which are predominantly found in the bronchi and peripheral vasculature. The labeled compound is used as a tracer to study the pharmacokinetics and metabolism of metoprolol. |
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The deuterated compound itself does not possess intrinsic pharmacological activity in vitro; its biological activity is identical to that of metoprolol. Metoprolol is a selective β₁-adrenoceptor antagonist with a Kᵢ of approximately 10-50 nM for β₁-receptors and significantly lower affinity for β₂-receptors. In vitro studies have demonstrated that metoprolol effectively inhibits isoproterenol-stimulated cAMP accumulation in cells expressing β₁-receptors. Metoprolol also shows anti-inflammatory, antitumor, and anti-angiogenic properties. The labeled compound is used as an internal standard for quantifying metoprolol in biological samples. |
| ln Vivo |
Metoprolol-d7 hydrochloride is not used as a therapeutic agent; its non-deuterated form, metoprolol, is an orally active β₁-blocker used in the treatment of hypertension, angina pectoris, and cardiac arrhythmias. Metoprolol has a bioavailability of approximately 50% after oral administration (due to first-pass metabolism) and is available in immediate-release and extended-release formulations. It is metabolized in the liver via cytochrome P450 2D6. The labeled compound is used in pharmacokinetic studies to accurately measure metoprolol concentrations in plasma and other biological matrices.
|
| Enzyme Assay |
In vitro receptor binding assays for metoprolol-d7 hydrochloride are not standard, as it is an analytical standard. The β₁-adrenoceptor antagonism of its non-deuterated form can be assessed using competition binding assays with [³H]CGP-12177 as a radioligand. Membranes prepared from cells expressing β₁-adrenergic receptors are incubated with varying concentrations of metoprolol and the radioligand. Non-specific binding is determined in the presence of excess propranolol. Bound radioactivity is separated by filtration and quantified by scintillation counting. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell culture experiments are not performed with metoprolol-d7 hydrochloride. When studying the effects of metoprolol in cellular systems, the non-labeled compound is used. Cells expressing β₁-adrenergic receptors are treated with metoprolol, and cAMP levels or downstream signaling pathways are measured. The labeled compound is used as an internal standard for LC-MS/MS analysis of metoprolol concentrations in cell culture media or lysates.
|
| Animal Protocol |
In vivo animal studies with metoprolol-d7 hydrochloride are not conducted, as it is an analytical standard. When used in pharmacokinetic studies, the labeled compound serves as an internal standard for the quantification of metoprolol in animal plasma or tissue samples. In typical protocols, animals are administered metoprolol, and blood samples are collected at various time points. The labeled internal standard is added to the samples before analysis by LC-MS/MS to ensure accurate and precise quantification.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of metoprolol-d7 hydrochloride itself are not characterized, as it is not a drug substance. Metoprolol has a bioavailability of approximately 50% after oral administration, with a half-life of 3-7 hours. It is metabolized primarily by cytochrome P450 2D6 to α-hydroxymetoprolol and O-demethylmetoprolol. Metoprolol is excreted in urine (95%). The deuterated compound is used as an internal standard to accurately quantify metoprolol in pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Metoprolol-d7 hydrochloride is not a therapeutic agent and has not been evaluated for toxicity in humans. Its non-deuterated form, metoprolol, is generally well-tolerated, with common side effects including bradycardia, fatigue, dizziness, and gastrointestinal disturbances. Contraindications include cardiogenic shock, severe bradycardia, and decompensated heart failure. The deuterated compound is for research use only and should be handled with standard laboratory precautions.
|
| References | |
| Additional Infomation |
Metoprolol-d7 hydrochloride is a stable isotope-labeled internal standard used in pharmacokinetic and metabolic studies of metoprolol. It is also known as (±)-metoprolol-d7 hydrochloride. The compound is used in analytical method development, method validation, and quality control applications for generic drug products. The incorporation of deuterium allows for accurate quantification of metoprolol in biological samples using mass spectrometry.
|
| Molecular Formula |
C15H19D7CLNO3
|
|---|---|
| Molecular Weight |
310.87
|
| Exact Mass |
303.16
|
| CAS # |
1219798-61-4
|
| Related CAS # |
Metoprolol;51384-51-1;Metoprolol succinate;98418-47-4;Metoprolol tartrate;56392-17-7;Metoprolol fumarate;80274-67-5
|
| PubChem CID |
76974368
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
20
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])(C([2H])([2H])[2H])NCC(COC1=CC=C(C=C1)CCOC)O.Cl
|
| InChi Key |
UKBBZNRSHOCRNP-ODLOEXKQSA-N
|
| InChi Code |
InChI=1S/C15H25NO3.ClH/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;/h4-7,12,14,16-17H,8-11H2,1-3H3;1H/i1D3,2D3,12D;
|
| Chemical Name |
1-(1,1,1,2,3,3,3-heptadeuteriopropan-2-ylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2168 mL | 16.0839 mL | 32.1678 mL | |
| 5 mM | 0.6434 mL | 3.2168 mL | 6.4336 mL | |
| 10 mM | 0.3217 mL | 1.6084 mL | 3.2168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
